ArticleScientific reports2025
Dexamethasone enhances intestinal glucose absorption and TMPRSS2 expression with implications for hyperglycaemia and infection risk.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long-term corticosteroid use, including dexamethasone, is associated with an increased risk of type 2 diabetes, leading to enhanced hepatic gluconeogenesis and peripheral insulin resistance. This study reveals that dexamethasone additionally acts as a potent inducer of the main intestinal glucose transporter, sodium-dependent glucose cotransporter 1 (SGLT1). In differentiated human Caco-2/TC7 intestinal cell monolayers, dexamethasone dose-dependently increased glucose transport by upregulating SGLT1 mRNA despite a reduction in glucose transporter 2 (GLUT2) mRNA. Dexamethasone similarly elevated SGLT1 expression in ileal enterocytes and induced GLUT2 mRNA in mice, supporting its role in enhancing intestinal glucose uptake. Given the extensive use of dexamethasone to treat COVID-19, we further assessed its impact on SARS-CoV-2 entry receptors in the intestine. Dexamethasone increased transmembrane protease, serine 2 (TMPRSS2) mRNA expression while decreasing angiotensin-converting enzyme 2 (ACE2) mRNA and protein levels, potentially exacerbating viral spread in the gut. Our findings suggest that dexamethasone promotes glucose absorption in the intestine, contributing to hyperglycaemia, and modulates expression of intestinal SARS-CoV-2 receptors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.